A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose administration to healthy adult subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Collaborator: Medivation, Inc.
• Treatments: Dextromethorphan

Criteria

Inclusion Criteria:

• Healthy adult subjects.

• Extensive or ultra-rapid metabolizers of CYP2D6 substrates, predicted by genotype.

Exclusion Criteria:

• Existence of significant medical conditions that would impact study results or pose unacceptable risks to study subjects.

• Pregnant or nursing females or females of childbearing potential who are unwilling or unable to use an acceptable method of contraception.

• Use of prescription or nonprescription drugs and dietary supplements within 7 days prior to the first dose of study medication.